NCI has renewed MUSC Hollings Cancer Center’s five-year Cancer Center Support Grant, with an overall rating of “outstanding.”
An analysis by researchers from the International Agency for Research on Cancer casts doubt on validity of an endpoint used in key studies of multi-cancer detection tests.
With NCI funding expected to remain flat through fiscal year 2025, health professionals and leaders in oncology should use this time to amp up institutional efforts to collaborate and rebuild trust in science, NCI Director Kimryn Rathmell said.
To address inequities in cancer health, NCI is collaborating with a diverse team of experts and cancer center directors—named the Cancer Equity Leaders (CEL)—to learn from communities and inform workforce development as well as outreach initiatives.
NCI is lowering paylines for R01 grants for established and new investigators to the 10th percentile, down from the 12th percentile in FY23.
NCI renewed the University of Chicago Medicine Comprehensive Cancer Center’s “comprehensive” designation and continued grant support for another five years.
Antonio C. Wolff, chair of the Breast Cancer Committee for the ECOG-ACRIN Cancer Research Group, will co-lead the Breast Cancer Steering Committee for NCI. He began the three-year term on April 1.
Next week, NCI will announce its plans for surviving on an austere budget given to it by Congress as fiscal year 2024 approaches the six-month mark.
Credit: National Cancer Institute, National Institutes of HealthHalfway into fiscal year 2024, NCI officials are crunching numbers, trying to find ways to live with an appropriation that, for the first time since sequestration, reduces the institute’s spending power.
The NCI Board of Scientific Advisors unanimously approved two new concepts and three reissued concepts at a meeting March 20.